unknown
Stage
1
Investors
About
Guard Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for diseases with significant unmet medical needs, particularly kidney diseases. The company’s research is centered on the endogenous protein Alpha-1-Microglobulin (A1M), which possesses cell-protective and antioxidative properties.
Explore Guard Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.